Background
==========

Breast cancer is the most common malignancy in women, and accounts for 15% of all cancers \[[@B1]\]. The accurate estimation of tumor size and extent in breast cancer is essential for surgical planning and minimizing local recurrence after surgery \[[@B2],[@B3]\], and recently, chest computed tomography (CT) has been used to detect pulmonary and hepatic metastasis in patients with breast cancer before surgery. However, chest CT screening is not currently recommended in operable and asymptomatic patients with breast cancer \[[@B4],[@B5]\], although the use of chest CT examinations in breast cancer patients is undoubtedly increasing. Furthermore, a review of the literature revealed that no study has yet addressed the use of chest CT for determining breast tumor size. Accordingly, the purpose of this study was to assess the value of chest CT for determining breast tumor size using pathology measurements as reference standards.

Methods
=======

Patients
--------

We retrospectively searched archived records in a practice specializing in breast surgery from April 2010 to January 2012 for breast cancer patients that underwent chest CT before surgical treatment. The inclusion criteria adopted were newly diagnosed, biopsy-proven, unifocal breast cancer with a positive chest CT scan. Finally, 285 patients (mean age, 48.79 years; range, 20--79 years) were included. Baseline characteristics of the study cohort are provided in Table [1](#T1){ref-type="table"}.

###### 

Clinicopathologic characteristics of the study subjects

  **Characteristics**          **Tumors \<20 mm on CT (*n*= 139)**   **Tumors ≥20 mm on CT (*n*= 146 )**   ***P*values**
  ---------------------------- ------------------------------------- ------------------------------------- ---------------
  Age (years)^a^               50.1±9 (31--78)                       47.5 ± 10 (20--79)                    0.249^b^
  *Stages*                                                                                                  
  IA                           106                                   9                                      
  IB                           0                                     0                                      
  IIA                          28                                    74                                     
  IIB                          0                                     29                                     
  IIIA                         1                                     19                                    0.724^c^
  IIIB                         1                                     1                                     
  IIIC                         3                                     14                                    
  *T stages*                                                                                                
  T1                           138                                   13                                    0.267^c^
  T2                           0                                     124                                   
  T3                           0                                     8                                     
  T4                           1                                     1                                     
  *N stages*                                                                                                
  N0                           107                                   81                                     
  N1                           28                                    33                                    0.467^c^
  N2                           1                                     18                                    
  N3                           3                                     14                                    
  ER status                                                                                                 
  Positive                     95                                    81                                    0.164^c^
  Negative                     44                                    65                                    
  PR status                                                                                                 
  Positive                     70                                    62                                    0.020^++^
  Negative                     69                                    84                                    
  *HER-2 amplification*                                                                                     
  Positive                     75                                    79                                    0.113^c^
  Negative                     64                                    67                                    
  Unknown                                                                                                  
  Histopathologic type                                                                                      
  Invasive ductal carcinoma    119                                   126                                   
  Invasive lobular carcinoma   6                                     7                                     
  Others^d^                                                                                                
  Histologic grade^e^                                                                                       
  Grade 1                      26                                    8                                     0.091^c^
  Grade 2                      82                                    73                                    
  Grade 3                      31                                    65                                    
  Unknown                                                                                                  
  Operation type                                                                                            
  Mastectomy                   17                                    33                                    0.051^c^
  Breast conserving surgery    122                                   113                                   

^a^ Mean values with standard deviations (numbers in parentheses are ranges).

^b^ Two-sample *t*- test.

^c^ Chi-squared test.

^d^ Others including invasive papillary carcinoma (*n*= 6), invasive micropapillary carcinoma (*n*= 5), mucinous carcinoma (*n*=4), metaplastic carcinoma (*n*=4), invasive tubular carcinoma (*n*= 3), invasive apocrine carcinoma (*n*= 3), neuroendocrine carcinoma (*n*=1), invasive carcinoma with squamous differentiation (*n*=1).

^e^ Scarff-Bloom-Richardson grade system.

ER, estrogen receptor; PR, progesterone receptor.

Gross and histopathologic examinations of surgical specimens were performed by staff pathologists. Cross-sections of formalin-fixed paraffin-embedded specimens were obtained at 5-mm intervals perpendicular to the line connecting the nipple and the tumor center. Specimens were examined microscopically using hematoxylin and eosin staining. Lesion sizes were measured and largest tumor diameter was defined as tumor size.

Histopathologic diagnosis revealed invasive ductal carcinoma (IDC) in 86%, invasive lobular carcinoma (ILC) in 4.5%, invasive papillary carcinoma in 2.1%, and othersin 7.4%. The parameters used for multidetector computed tomography (MDCT) (Somatom Sensation 16 or 64 scanners, Siemens Medical Solutions, Forchheim, Germany) examinations were as follows: 100--120 kVp, 170 mAs, 5-mm collimation, a 10 mm/s table feed with a 1-s rotation time, 5.0-mm slice thickness, and 2.5--5.0 mm intervals. Synthetic sagittal and coronal images were reformatted at intervals of 3 mm and fully covered the region from anterior skin to the back of the chest. The effective dose for chest CT was 4.0 mSv, based on a standard patient model using an anthropomorphic phantom, and a conversion factor of 0.017 mSv/(mGy.cm) was used to convert dose-length product to effective dose \[[@B6]\]. Prior to chest CT, all patients fasted for \>6 h. Iopromide (120 mL; Ultravist; Bayer Schering Pharma, Berlin) was injected intravenously at a rate of 4 mL/s, and CT images were obtained 30--40 s later. Our institutional review board approved this retrospective study, and the requirement for informed patient consent was waived.

Image analysis
--------------

A subspecialty-trained chest radiologist and a third-year radiology resident retrospectively measured maximum diameters of breast tumors on CT images by consensus and compared these with pathologic results. CT determined tumor sizes were also analyzed for concordance with pathologic tumor sizes.

Concordance between CT and pathologic diameters was defined as a tumor size difference of \<5 mm. When a CT measured size was \>5 mm smaller than pathologic tumor size, CT determined tumor size was considered an underestimation, and conversely, when CT size was \>5 mm larger than pathologic tumor size, it was considered an overestimation. In addition, concordance rates between IDC and non-IDC patients and between patients with a CT determined tumor diameter of \<20 mm (Group 1) and ≥20 mm (Group 2) were compared.

Statistical analysis
--------------------

Maximum chest CT and pathology determined tumor sizes were compared by linear regression and Spearman's rho correlation analysis. The chi-squared test was used to analyze concordances rates between chest CT and pathology with respect to tumor size and histologic type. Statistical significance was accepted at the 95% confidence level (*P*\<0.05). A commercially available software program was used for data processing and analysis (PASW, version 17.0; SPSS, Chicago, IL, USA).

Results
=======

Overall, longest tumor diameters as determined by chest CT (average, 21 mm, range, 2--74 mm) and pathology (average, 22 mm; range, 3--90 mm) were not significantly different (*P* = 0.059)*,* and a linear relation was found between the two (pathology determined tumor size = 1.086 × CT determined tumor size - 1.141; Spearman's rho correlation coefficient, 0.84; *P*\<0.001).

Tumor sizes were concordant in 228 of the 285 patients (80%). However, 36 tumors (12.7%) were underestimated by CT by an average of 12 mm (range, 6--36 mm) and 21 tumors (7.4%) were overestimated by an average of 10 mm (range, 6--19 mm). The concordance rate was higher for tumors of \<20 mm (88.5% *vs*. 71.9% for tumor size \<20 mm *vs*. tumor size ≥20 mm, *P*\<0.001) and for IDC (82.4% *vs*. 65.0% for IDC *vs*. non-IDC, *P =* 0.011) (Table [2](#T2){ref-type="table"}).

###### 

Comparison of CT and pathologically determined tumor sizes

                                      **Size (median ± SD)**   ***Concordance with CT*(%)**   ***Discordance with CT*(%)**                               
  ---------------------- ------------ ------------------------ ------------------------------ ------------------------------ --------------------------- ----------------------------
                         ***n*(%)**   **CT**                   **Pathology**                                                 ***Overestimated by CT***   ***Underestimated by CT***
  Overall                285 (100)    19±10                    20±13                          228 (80)                       21 (7)                      36 (13)
  CT group^a^                                                                                                                                             
  Group 1 (\<20 mm)      139 (49)     15±5                     13±4                           123 (88)                       15 (11)                     1 (1)
  Group 2 (**≥**20 mm)   146 (51)     27±10                    30±13                          105 (72)                       6 (4)                       35 (24)
  Tumor type^b^                                                                                                                                           
  IDC                    245 (86)     20±10                    20±12                          202 (83)                       18 (7)                      25 (10)
  Non-IDC                40 (14)      18±11                    19±14                          26 (65)                        3 (8)                       11 (28)

^a^ Comparison of group 1 to group 2, *P*\<0.001.

^b^ Comparison across tumor types, *P* = 0.011.

Discussion
==========

A number of imaging modalities are used to assess tumor size and extent in breast cancer to determine optimal treatment. Mammography and ultrasonography are the first choices for the screening and diagnosis of breast cancer, but mammography is limited in premenopausal women with dense breasts and ultrasonography is not reliable enough to visualize tumor extensions when tumors exhibit extensive intraductal spread \[[@B7]\]. Breast magnetic resonance imaging (MRI) has attracted much attention recently because its ability to detect breast lesions sufficient to allow the accurate visualization of intraductal lesions around main tumors \[[@B7],[@B8]\]. However, although MRI offers the advantage of sensitivity, it tends to overestimate tumor size and is limited by a relatively high false-positive rate, and thus, requires additional biopsies and increases patient anxiety, time, and costs \[[@B9]-[@B11]\]. In addition, MRI cannot be performed in patients with claustrophobia and is usually performed in the prone position, whereas surgery is performed with the patient supine. ChestCT examinations, on the other hand, are performed in the supine position, and thus, the positions of breasts in chest CT images better matches the surgical approach. Furthermore, due to the technological improvements offered by MDCT, several authors have concluded that CT of the breast provides an accurate preoperative means of assessing tumor extent and size \[[@B8],[@B12]-[@B14]\]. However, breast CT in these reports had different acquisition technique with chest CT and is rarely used in present clinical practice, because the field of view is limited to the breast region and examinations require multiple scans, including precontrast CT scan and postcontrast CT scan at 70 to 100 s after contrast administration \[[@B13],[@B15],[@B16]\], or a dynamic acquisition technique (1, 3, and 8 min after contrast administration), which inevitably increases radiation dose \[[@B17]\]. In previous studies \[[@B17]-[@B19]\], the radiation dose required for breast CT was reported to be 28 mSv, which is approximately 10 times greater than that used for standard mammographic examinations (2.8 mSv), and seven times higher than that required for a chest CT examination.

For the assessment of tumor size in breast cancer, several authors have addressed the accuracies of mammography, ultrasonography (US), and magnetic resonance imaging (MRI) \[[@B20]-[@B24]\]; Ramirez *et al*. \[[@B22]\] concluded that generally, breast mammography determined tumor size correlated better with histopathologic size than MRI or US determined tumor sizes. However, MRI is regarded to be more accurate than mammography or ultrasonography in the ILC subtype, which tends to underestimate the sizes of ILC in up to 70%, and 80% of cases, respectively \[[@B23],[@B24]\]. However, to the best of our knowledge, no previous study has addressed tumor size estimation by chest CT in breast cancer patients.

Because the incidence of metastasis is low and false-positive findings are more common than true-positive findings \[[@B4],[@B5]\], the current National Comprehensive Cancer Network (NCCN) guidelines do not recommend the routine use of chest CT in operable breast cancer. Nevertheless, chest CT exanimations are being increasingly used in breast cancer to evaluate pulmonary and hepatic metastases \[[@B5],[@B23],[@B24]\]. Somewhat surprisingly, no report has been issued regarding the predictive value of chest CT for the evaluation of tumor size in breast cancer. In the present study, we found a positive correlation between chest CT and pathologically determined tumor sizes and that tumors sizes differed by \<5 mm in 80% of our cohort. Furthermore, the concordance rate between CT and pathologic findings was higher for breast tumors of \<20 mm and for those of the IDC histologic subtype.

Although current guidelines and available evidence do not support the routine preoperative chest CT evaluation of operable breast cancer, in some patients with a respiratory or abdominal symptom or who deny other imaging modalities, chest CT could provide an alternative means of evaluating tumor size, especially when the tumor is \<20 mm of the IDC subtype.

This study had several limitations that warrant consideration. First, it is inherently limited by its retrospective design. In particular, the study is subject to selection bias, because women were selected for chest CT at the discretion of a breast surgeon, and breast cancers not visualized by chest CT were not included in the study. Second, we did not compare CT determined tumor sizes with ultrasonography, mammography, or breast MRI determined sizes, because not all patients underwent ultrasonography, mammography, or MRI, and because imagings were performed at different times. A prospective study is required to compare the abilities of chest CT, ultrasonography, mammography, and breast MRI to determine breast cancer size. Third, formalin fixation affects solid tissue measurements. Pritt and colleagues \[[@B25]\] observed 4% of breast cancer specimens decreased in size after overnight formalin fixation and that 40% shrank after processing and mounting.

Conclusions
===========

The present study shows that chest CT can be used to predict breast tumor size reliably in patients with breast cancer. In fact, chest CT determined breast tumor sizes were found to be well correlated with pathology-determined sizes, and for most, the size difference was \<5 mm. In addition, the concordance rate between chest CT and pathology was found to be greater for breast tumors of \<20 mm and for the IDC subtype.
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